KCL-HO-1i

KCL-HO-1i is an orally active heme oxygenase-1 (HO-1) inhibitor (rat HO-1: IC50 = 123 nM) and human HO-1: IC50 = 128 nM) . KCL-HO-1i targets immunosuppressive LYVE-1+ perivascular tumor-associated macrophages (PvTAMs) in the tumor microenvironment (TME), reduces PvTAM-mediated immune exclusion. KCL-HO-1i demonstrates synergistic anti-tumor efficacy with chemotherapy in MMTV-PyMT spontaneous breast cancer mice or C57Bl/6 mice bearing subcutaneous MN-MCA1 sarcomas. KCL-HO-1i can be used for the study of cancer[1].

Product Specifications

UNSPSC

12352100

Target

Heme Oxygenase (HO)

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CCC1=C(C)C2=N/C1=C\C3=C(C)C(CC)=C4N3[Sn](OP([O-])([O-])=O)(OP([O-])([O-])=O)N(/C(C(C)=C/5CCC(O)=O)=C\2)C5=C/C6=N/C(C(C)=C6CCC(O)=O)=C\4.[Sn+2].[Sn+2]

Molecular Formula

C34H36N4O12P2Sn3

Molecular Weight

1110.75

References & Citations

[1]Bahri M, et al. An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer. Sci Transl Med. 2025 Aug 6;17 (810) :eads3085.